R&D Partnerships Wesana's BrainStorm Lab venture with the University of South Carolina demonstrates a model for joint research in traumatic brain injury. Exploit this by pursuing collaborations with academic centers, hospitals, and CROs to co-develop psychedelic-based therapies for TBI and related neuropsychiatric conditions, potentially sharing costs and speeding development.

Corporate Wellness A prior Tyson Foods collaboration indicates corporate interest in reducing stigma around plant medicines. Target enterprise wellness programs with mid-sized to large employers, offering compliant psychedelic-therapy pilots and mental health solutions integrated with employee assistance initiatives.

Asset Monetization The sale of SANA-013 assets to Lucy Scientific Discovery signals a pathway for asset monetization and potential licensing deals. Explore partnerships to license or acquire other assets, co-developments, or revenue-sharing arrangements with acquirers or other players in the psychedelics space.

Development Services With a small team and modest funding, Wesana could benefit from outsourced CRO, GMP manufacturing, regulatory affairs, and clinical data management partners to advance psychedelic mental health programs. Position as a preferred development partner to accelerate timelines.

Digital Growth The tech stack shows reliance on standard web and cloud tools; this creates opportunities to offer digital patient engagement platforms, secure data collaboration, analytics for clinical outcomes, and scalable digital marketing to boost visibility and trial recruitment.